K
Kathy Savas
Researcher at Cleveland Clinic
Publications - 12
Citations - 995
Kathy Savas is an academic researcher from Cleveland Clinic. The author has contributed to research in topics: Kidney transplantation & Mycophenolic acid. The author has an hindex of 9, co-authored 12 publications receiving 972 citations.
Papers
More filters
Journal ArticleDOI
Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine.
Stuart M. Flechner,David A. Goldfarb,Charles S. Modlin,Jingyuan Feng,Venkatesh Krishnamurthi,Barbara Mastroianni,Kathy Savas,Daniel J. Cook,Andrew C. Novick +8 more
TL;DR: Calcineurin inhibitor drug avoidance with basiliximab induction and sirolimus provides comparable 1-year transplant outcomes, with significantly better renal function in primary renal allograft recipients.
Journal ArticleDOI
The impact of sirolimus, mycophenolate mofetil, cyclosporine, azathioprine, and steroids on wound healing in 513 kidney-transplant recipients.
Stuart M. Flechner,Lingmei Zhou,Ithaar Derweesh,Barbara Mastroianni,Kathy Savas,David A. Goldfarb,Charles S. Modlin,Venkatesh Krishnamurthi,Andrew C. Novick +8 more
TL;DR: During a 10-year period marked by changing recipient demographics, the introduction of MMF and SRL did not result in a significant increase in transplant wound-healing complications.
Journal ArticleDOI
Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs.
Stuart M. Flechner,David A. Goldfarb,Kim Solez,Charles S. Modlin,Barbara Mastroianni,Kathy Savas,Denise C Babineau,Sunil M. Kurian,Daniel R. Salomon,Andrew C. Novick,Daniel J. Cook +10 more
TL;DR: This study of low to moderate risk patients demonstrates that excellent 5-year kidney transplant outcomes can be achieved without CNI drugs, when therapeutic drug monitoring of sirolimus is employed.
Journal ArticleDOI
Alemtuzumab Induction and Sirolimus Plus Mycophenolate Mofetil Maintenance for CNI and Steroid‐Free Kidney Transplant Immunosuppression
Stuart M. Flechner,Peter J. Friend,Jens Brockmann,Hazem R. Ismail,Miguel Zilvetti,David A. Goldfarb,Charles S. Modlin,Barbara Mastroianni,Kathy Savas,A. Devaney,Matthew J. Simmonds,Daniel J. Cook +11 more
TL;DR: Overall infection rates were low, but 2 patients developed severe acute respiratory distress syndrome (ARDS) at month 3 and 7, respectively, resulting in mortality in one and a graft loss in the other.
Journal ArticleDOI
The Influence of Various Maintenance Immunosuppressive Drugs on Lymphocele Formation and Treatment After Kidney Transplantation
Mahesh Goel,Stuart M. Flechner,Lingme Zhou,Barbara Mastroianni,Kathy Savas,Ithaar Derweesh,Pratik Patel,Charles S. Modlin,David A. Goldfarb,Andrew C. Novick +9 more
TL;DR: The combination of sirolimus/MMF/P, obesity with a body mass index of greater than 30 kg/m and acute rejection are independent risk factors for lymphocele formation and treatment after kidney transplantation.